Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Violet Therapeutics
AddedFeb 15, 2024
UpdatedMay 31, 2026
Violet Therapeutics

Violet Therapeutics

Preclinical biotech developing first-in-class CNS therapies via the CONNECT platform, targeting EphB3 for neurodegenerative diseases.

HQ
Norwalk, CT, US
Founded
2021
Overview
Compare
Fundraising
Employees
News
Website

Violet Therapeutics is a preclinical-stage biotechnology company developing first-in-class therapies for neurodegenerative diseases by mapping disease-relevant cell-to-cell signaling interactions in the brain. The company's proprietary CONNECT platform enables discovery of novel targets emerging from cellular interaction networks rather than genetic association alone, supporting the development of a pipeline of small-molecule therapeutics addressing neuroinflammation and related CNS pathologies.

The company's lead program is a small molecule inhibitor of EphB3, a receptor tyrosine kinase that mediates microglia-astrocyte interactions driving glial dysfunction in neurodegenerative disease. Synaptic loss is one of the strongest predictors of cognitive decline in Alzheimer's disease and other neurodegenerative conditions, and Violet's lead program is designed to address this core pathology through glial-mediated synaptic preservation and repair.

Violet Therapeutics - Similar Companies

Allyx Therapeutics logo

Allyx Therapeutics

allyxthera.com

Spinogenix logo

Spinogenix

spinogenix.com

VistaGen Therapeutics logo

VistaGen Therapeutics

Neuro3 Therapeutics logo

Neuro3 Therapeutics

Asha Therapeutics logo

Asha Therapeutics

Ilios logo

Ilios

iliostx.com

Vian Therapeutics logo

Vian Therapeutics

viantx.com

Aztherapies logo

Aztherapies

Souvien Therapeutics logo

Souvien Therapeutics

Visum Pharma logo

Visum Pharma

visumpharmainc.com

NeuroX1 logo

NeuroX1

neurox1.com

Aprinoia Therapeutics logo

Aprinoia Therapeutics

aprinoia.com

Eikonizo Therapeutics logo

Eikonizo Therapeutics

eikonizo.com

Therini Bio logo

Therini Bio

therinibio.com

NeuroTherapia logo

NeuroTherapia

neurotherapia.com

Violet Therapeutics - Quick Facts

Who are Violet Therapeutics' competitors?

Companies similar to Violet Therapeutics include Allyx Therapeutics, Spinogenix, VistaGen Therapeutics and Neuro3 Therapeutics.

When was Violet Therapeutics founded?

Violet Therapeutics was founded in 2021.

Where is Violet Therapeutics' headquarters located?

Violet Therapeutics' headquarters is located in Norwalk, CT, US.

When was Violet Therapeutics' last funding round?

Violet Therapeutics' most recent funding round was for $10.6M (USD) in May 2023.

How much has Violet Therapeutics raised to-date?

As of May 5, 2023, Violet Therapeutics has raised a total of $15.3M (USD).

How many employees does Violet Therapeutics have?

Violet Therapeutics has 6 employees as of Feb 5, 2024.

Violet Therapeutics - Classification

Industry
  • Biotechnology
Tags
  • CNS Therapeutics
  • Drug Discovery
  • Neurodegenerative Disease
  • Small Molecule
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 9 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
SIC
  • 2800Chemicals And Allied Products
  • 2830Drugs
  • 2834Pharmaceutical Preparations